-
Tytuł:
-
The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
-
Autorzy:
-
Wu Z; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Zheng Y; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Xie W; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Li Q; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Zhang Y; Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Ren B; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Cai L; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Cheng Y; Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Tang H; Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Su Z; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. Electronic address: .
Wu ZB; Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China; Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: .
-
Źródło:
-
Molecular and cellular endocrinology [Mol Cell Endocrinol] 2020 Dec 01; Vol. 518, pp. 111033. Date of Electronic Publication: 2020 Sep 15.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Limerick : North Holland Publishing
Original Publication: Amsterdam, North-Holland.
-
MeSH Terms:
-
Adenoma/*drug therapy
Dopamine Agonists/*therapeutic use
Drug Resistance, Neoplasm/*genetics
Pituitary Neoplasms/*drug therapy
Adenoma/genetics ; Adenoma/pathology ; Animals ; Autophagy-Related Protein 7/physiology ; Cell Line, Tumor ; Dopamine Agonists/pharmacology ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/physiology ; Pituitary Neoplasms/genetics ; Pituitary Neoplasms/pathology ; Prolactinoma/drug therapy ; Prolactinoma/genetics ; Prolactinoma/pathology ; RNA, Long Noncoding/physiology ; Rats ; Signal Transduction/genetics ; Signal Transduction/physiology ; Somatotrophs/metabolism ; Somatotrophs/pathology
-
Contributed Indexing:
-
Keywords: ATG7; Dopamine agonist; Prolactinoma; lncRNA H19; miRNA-93
-
Substance Nomenclature:
-
0 (Atg7 protein, rat)
0 (Dopamine Agonists)
0 (H19 long non-coding RNA)
0 (MIRN93 microRNA, human)
0 (MicroRNAs)
0 (Mirn93 microRNA, rat)
0 (RNA, Long Noncoding)
EC 6.2.1.45 (ATG7 protein, human)
EC 6.2.1.45 (Autophagy-Related Protein 7)
-
Entry Date(s):
-
Date Created: 20200918 Date Completed: 20210629 Latest Revision: 20231213
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.mce.2020.111033
-
PMID:
-
32946927
-
Dopamine agonists (DAs), such as cabergoline and bromocriptine, are the first-line clinical treatment for prolactinomas. Our previous study demonstrated that long noncoding RNA H19 expression is frequently downregulated in human primary pituitary adenomas and is negatively correlated with tumor progression. However, the significance and mechanism of H19 in the DA treatment of prolactinomas are still unknown. In this study, we reported that H19 had a synergistic effect with DA treatment on prolactinomas in vitro and in vivo. Mechanistically, H19 promoted ATG7 expression in pituitary tumor cells by inhibiting miR-93a expression. In addition, a potential binding site between miR-93 and H19 was confirmed, and low expression of miR-93 was previously found in DA-resistant prolactinomas. Furthermore, we showed that miR-93a regulates ATG7 expression by targeting ATG7 mRNA. In conclusion, our study has identified the role of the H19-miR-93-ATG7 axis in DA treatment of prolactinomas, which may be a potential therapeutic target for human prolactinomas.
(Copyright © 2020. Published by Elsevier B.V.)
